MarliseRachaelLuskinMDMSCE

Hematologic Oncology

Assistant Professor Adult Leukemia Dana-Farber Cancer Institute

Dr. Luskin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Brigham and Women's HospitalChief Residency, Internal Medicine, 2015 - 2016
University of PennsylvaniaMSCE, Epidemiology, 2013 - 2015
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2012 - 2015
Brigham and Women's HospitalResidency, Internal Medicine, 2009 - 2012
Perelman School of Medicine at the University of PennsylvaniaClass of 2009

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML Start of enrollment: 2018 Jul 24
Recruiting
Phase 1
Ruxolitinib in Thrombocythemia and Polycythemia Vera Start of enrollment: 2022 Mar 21
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Venetoclax Plus Inotuzumab for B-ALL Start of enrollment: 2021 Sep 24
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL Start of enrollment: 2017 Oct 30
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Join now to see all

PubMed

Abstracts/Posters

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies
Marlise Luskin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Pre...
Marlise Luskin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration
Marlise Luskin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
Marlise Luskin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Sleep Disturbance Among Patients with Myelodysplastic Syndromes and Acute Leukemia
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Clinical Characteristics of GNB1 and GNAS Mutations in an Unselected Cohort of 6,343 Patients with Hematologic Abnormalities
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
How I Treat Acute Lymphocytic Leukemia: Insight From the Experts
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Boston College Grad Celebrates ‘Double Graduation’ from School and Cancer TreatmentJune 6th, 2021
Ruxolitinib in Thrombocythemia and Polycythemia VeraNovember 25th, 2020
CML & Pregnancy: Patient & Partner ConsiderationsJune 5th, 2018
Join now to see all